Policy red envelope: the health care industry financing momentum is optimistic

On June 24, the General Office of the State Council issued the “Guiding Opinions on Promoting and Regulating the Development of Big Data Application for Health Care Medical ”, and proposed 14 key points to accelerate the construction of a unified and authoritative and interconnected population health information platform and foster new formats for health care big data applications. Tasks and projects, further clarify and promote the "Internet + health care" services, smart medical, telemedicine and medical information and other sub-sectors will be supported by the state.

2016 is the first year of the “Thirteenth Five-Year Plan”. The pharmaceutical bio-industry policy related to “Healthy China” will continue to fall, and the medical and health industry will usher in historic development opportunities.

Judging from the overall development space of the industry, China's health industry currently accounts for less than 5% of GDP. Compared with the proportion of more than 10% in developed countries, the gap is still large. Industry insiders predict that by 2020, the scale of investment in health industry brought by “Healthy China” is expected to reach 10 trillion yuan.

Nowadays, the policy dividend has begun to appear. The quarterly report released by the China Research Institute showed that the financing of the health care industry grew steadily in the second quarter, and the pharmaceutical industry developed well.

VC/PE financing develops steadily

Policy red envelope: the health care industry financing momentum is optimistic

CVSource statistics of financial data products under the investment information show that in the second quarter of 2016, there were 28 cases of VC/PE financing in the medical and health field, which was 40.4% lower than the 47 cases in the first quarter of 2016; the financing scale was 1.506 billion US dollars, an increase of 23.9%. %; the average transaction amount was US$54 million, an increase of 107.69% from the previous quarter's US$26 million, a decrease of 67.06% year-on-year. The total transaction amount remained basically the same, so the average transaction amount more than doubled. Although the number of financing cases in the second quarter is currently on a downward trend, the average size of transactions has increased substantially.

Pharmaceutical Gelatin

Pharmaceutical Gelatin,Pharmaceutical Gelatin For Oil Soft,Pharmaceutical Grade Gelatin,High Bloom Pharmaceutical Gelatin

Hebei Haodong Biological Technology Co.,Ltd. , https://www.hdgelatin.com